Diagnosing the Problem: Exploring the Effects of Consolidation and Anticompetitive Conduct in Healthcare Markets, Hearing Before the Subcommittee on Antitrust, Commercial and Administrative Law of the Committee on the Judiciary, House of Representatives, One Hundred Sixteenth Congress, First Session, March 7, 2019 [open pdf - 52MB]
This is the March 7, 2019 hearing on "Diagnosing the Problem: Exploring the Effects of Consolidation and Anticompetitive Conduct in Healthcare Markets," held before the U.S. House Subcommittee on Antitrust, Commercial and Administrative Law of the Committee on the Judiciary. From the opening statement of David Cicilline: "Americans spend, roughly $1,200 on average on prescription drugs every year, which is more than people in any other country. The average cost of a hospital stay for a child with cancer is $40,000. The price for many types of organ transplants and post-operation treatment is more than a million dollars. Even a short ambulance ride to the hospital without medical care may cost patients thousands of dollars. These outrageous, unsustainable, and immoral costs are ruining lives. Prices are skyrocketing and people are dying or bankrupted as a result. [...] The American people deserve a government that is in their corner fighting for them to take on drug profiteering and other barriers to affordable healthcare." Statements, letters, and materials submitted for the record include those of the following: Fiona Scott Morton, Michael Kades, Martin Gaynor, and Craig L. Garthwaite.
Serial No. 116-8
U.S. Government Publishing Office: http://www.gpo.gov/